Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Core Laboratories N.V. (CLB) Stock Price
News articles about Core Laboratories N.V. (NYSE:CLB) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Core Laboratories N.V. earned a news impact score of 0.24 on Accern’s scale. Accern also gave news headlines about the oil and gas company an impact score of 45.8676456661368 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Investors should Buy on Stock: Core Laboratories NV (CLB) – Street Observer (press release) (streetobserver.com)
- Core Laboratories’ Dividend Yield Curve (marketrealist.com)
- Core Laboratories NV (NYSE:CLB) Stock Traded Over Its 50 Day Moving Average – First News 24 (firstnewspaper24.com)
- Core Laboratories NV – Value Analysis (NYSE:CLB) : September 19, 2017 (finance.yahoo.com)
- Core Laboratories NV breached its 50 day moving average in a Bullish Manner : CLB-US : September 18, 2017 (finance.yahoo.com)
Several research analysts recently commented on the company. Royal Bank Of Canada set a $145.00 price target on Core Laboratories N.V. and gave the stock a “buy” rating in a research note on Saturday, June 17th. BidaskClub upgraded Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Piper Jaffray Companies set a $97.00 price target on Core Laboratories N.V. and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Zacks Investment Research upgraded Core Laboratories N.V. from a “hold” rating to a “buy” rating and set a $116.00 price target on the stock in a research note on Monday, June 12th. Finally, ValuEngine cut Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, June 6th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $113.58.
Shares of Core Laboratories N.V. (NYSE:CLB) opened at 96.59 on Friday. The firm’s 50-day moving average price is $92.99 and its 200 day moving average price is $103.90. Core Laboratories N.V. has a 52 week low of $86.55 and a 52 week high of $125.83. The firm has a market cap of $4.26 billion, a PE ratio of 59.26 and a beta of 1.60.
Core Laboratories N.V. (NYSE:CLB) last released its earnings results on Monday, July 24th. The oil and gas company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.01. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The business had revenue of $163.90 million for the quarter, compared to the consensus estimate of $168.23 million. During the same period last year, the business earned $0.35 earnings per share. The firm’s revenue for the quarter was up 10.7% compared to the same quarter last year. Equities analysts anticipate that Core Laboratories N.V. will post $1.99 EPS for the current year.
About Core Laboratories N.V.
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.